DNAe, the inventor of semiconductor-based genomic analysis technologies, and the developer of a new game-changing test for bloodstream infections that can lead to sepsis, announces that new data will be presented on its LiDia® Bloodstream Infection (BSI) test(1)(2) at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in Madrid, Spain, 21-24th April, 2018.
A demonstration of the blood-to-result workflow for LiDia® BSI will be previewed at DNAe’s booth at ECCMID.
Dr Steve Allen, CEO of DNAe Group Holdings, commented: “ECCMID comes at a pivotal time in our journey to bring this vital rapid diagnostic test to market. We are pleased to present key data and look forward to reaching more of the infectious disease community at the event this year. The congress gives us an excellent opportunity to showcase the LiDia® BSI closed cartridge-based test for the first time to a wide clinical audience at our stand, and to demonstrate its potential to support faster and more informed treatment of sepsis.”
Details of the poster presentation are as follows:
Poster Presentation – #P1960
Title: Rapid Detection of Clinically-Confirmed Bloodstream Pathogens in Culture-Negative Specimens'
Time and Date: 12:30 pm - 1:30 pm CEST, Tuesday, 24th April
Session: Diagnostic Approaches in Bacterial Bloodstream Infection
Location: Paper Poster Arena
The abstract is available online, here.
DNAe’s Dr Steve Allen, Nick McCooke, Dr Nour Shublaq, Dr Nicola Casali and Alexandra Barr will be available to discuss the data. To arrange a meeting, email firstname.lastname@example.org.
LiDia® BSI Demonstrations
Demonstrations will take place at DNAe’s booth between the following times:
12:00 noon – 6 pm CEST, Saturday, 21st April
9.30 am – 5 pm CEST, Sunday, 22nd April
9.30 am – 5 pm CEST, Monday, 23rd April
9.30 am – 2 pm CEST, Tuesday, 24th April
Location: Booth #104
If you would like to reserve a demonstration timeslot please RSVP in advance online, here.
Operating as a closed cartridge-based test, LiDia® BSI utilizes highly sensitive sample preparation and semiconductor-based PCR analysis to rapidly identify pathogens and key antibiotic resistance markers. Aiming to deliver clinically actionable results straight from raw blood specimens in under 3 hours, LiDia® BSI will aid patient management by offering a significant reduction in time-to-result compared to the current standard of culture-based diagnosis, which generally requires several days to produce a result.